# GLP-1 users face 6 rebound risks after stopping the weight-loss drugs

- URL: https://talkfuse.com/story/glp-1-users-face-6-rebound-risks-after-stopping-the-weight-loss-drugs/
- Published: 2026-11-12T21:17:35+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/12/health/doctor-reveals-6-rebound-risks-glp-1-users-face-after-stopping/
- Topics: Health, Medicine, World

## Key points

- Hunger and cravings may return after stopping GLP-1 medicines.
- Trial participants regained much of their lost weight.
- Health improvements can fade without ongoing management.

## Summary

A doctor has outlined six possible rebound effects for people who stop taking GLP-1 medicines used for weight management and diabetes. The risks matter because many patients discontinue treatment within a year, while obesity is generally treated as a chronic condition that may need ongoing management.

The article highlights renewed hunger and cravings, weight regain, and worsening health indicators such as blood sugar, blood pressure and cholesterol; improvements in fatty liver disease may also fade. In one semaglutide trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping, while a tirzepatide trial found those switched to placebo regained more than half over the following year. The article also notes that people may stop because of side effects or medical concerns, and recommends discussing decisions with a doctor.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.